London - Pfizer's quarterly revenue rose about 11%, driven by sales of newer drugs and the acquisition of hospital products company Hospira last year.
The largest US drugmaker's revenue rose to $13.15bn in the second quarter from $11.85bn, a year earlier.
The company's net income fell to $2.02bn, or 33 cents per share, from $2.63bn, or 42 cents per share.
Pfizer in April terminated its $160bn tax inversion deal to acquire Irish drugmaker Allergan.
Read Fin24's top stories trending on Twitter: Fin24’s top stories